share_log

Philip (Phil) Powell Buys 19,481 Shares of INOVIQ Ltd (ASX:IIQ) Stock

Philip (Phil) Powell Buys 19,481 Shares of INOVIQ Ltd (ASX:IIQ) Stock

菲利普(Phil)鲍威尔购买了INOVIQ Ltd(澳大利亚证券交易所股票代码:IIQ)的19,481股股票
Financial News Live ·  2023/03/09 09:40

INOVIQ Ltd (ASX:IIQ – Get Rating) insider Philip (Phil) Powell acquired 19,481 shares of INOVIQ stock in a transaction dated Friday, March 3rd. The stock was bought at an average price of A$0.56 ($0.38) per share, for a total transaction of A$10,909.36 ($7,321.72).

INOVIQ Ltd(澳大利亚证券交易所股票代码:IIQ — 获取评级)内部人士菲利普(菲尔)鲍威尔在3月3日星期五的一笔交易中收购了19,481股INOVIQ股票。该股以每股0.56澳元(0.38美元)的平均价格买入,总交易额为10,909.36澳元(合7,321.72美元)。

Philip (Phil) Powell also recently made the following trade(s):

菲利普(菲尔)鲍威尔最近还进行了以下交易:

Get
获取
INOVIQ
INOVIQ
alerts:
警报:
  • On Monday, March 6th, Philip (Phil) Powell acquired 20,000 shares of INOVIQ stock. The stock was bought at an average price of A$0.57 ($0.38) per share, for a total transaction of A$11,400.00 ($7,651.01).
  • On Wednesday, March 1st, Philip (Phil) Powell acquired 18,518 shares of INOVIQ stock. The stock was bought at an average price of A$0.54 ($0.36) per share, for a total transaction of A$9,999.72 ($6,711.22).
  • 3月6日星期一,菲利普(菲尔)鲍威尔收购了20,000股INOVIQ股票。该股以每股0.57澳元(0.38美元)的平均价格买入,总交易额为11,400.00澳元(合7,651.01美元)。
  • 3月1日星期三,菲利普(菲尔)鲍威尔收购了18,518股INOVIQ股票。该股以每股0.54澳元(0.36美元)的平均价格买入,总交易额为9,999.72澳元(合6,711.22美元)。

INOVIQ Price Performance

INOVIQ 价格表现

The company has a debt-to-equity ratio of 3.73, a current ratio of 5.28 and a quick ratio of 9.52.

该公司的债务与权益比率为3.73,流动比率为5.28,速动比率为9.52。

INOVIQ Company Profile

INOVIQ 公司简介

(Get Rating)

(获取评分)

INOVIQ Ltd engages in the research, development, and commercialization of diagnostic and exosome-based products to enhance the diagnosis and treatment of cancer and other diseases in Australia and the United States. The company offers hTERT test, an immunocytochemistry test used as an adjunct to urine cytology testing for bladder cancer; and EXO-NET for capturing and isolating exosomes from liquid biopsy sample.

INOVIQ Ltd从事诊断和基于外泌体产品的研究、开发和商业化,以增强澳大利亚和美国癌症和其他疾病的诊断和治疗。该公司提供hTERT测试,这是一种免疫细胞化学测试,用作膀胱癌尿液细胞学检测的辅助手段;以及用于从液体活检样本中捕获和分离外泌体的EXO-NET。

Further Reading

进一步阅读

  • REV Group Hits A Wall Despite Results And Outlook
  • Oil Tankers In Buy Range After Breaking Out Of Bases
  • United Natural Foods Under Delivered...Did the Market Overreact?
  • Can Cricut Stock Jump Higher In 2023?
  • 10 Best Consumer Staples ETFs
  • 尽管业绩和前景展望,REV 集团仍陷入困境
  • 油轮突破基地后进入买入区间
  • 联合天然食品交付不足... 市场反应过度了吗?
  • Cricut 的股票能否在 2023 年上涨呢?
  • 十大最佳必需消费品ETF

Receive News & Ratings for INOVIQ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INOVIQ and related companies with MarketBeat.com's FREE daily email newsletter.

每天接收 INOVIQ 的新闻和评级 -在下面输入您的电子邮件地址,即可通过Marketbeat.com的免费每日电子邮件时事通讯接收INOVIQ及相关公司的最新新闻和分析师评级的简明每日摘要。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发